diaDexus gets US patent for heart disease test:
This article was originally published in Clinica
Executive Summary
diaDexus has been issued with a US patent covering its blood test for a patient's susceptibility to atherosclerosis. The immunoassay-based test measures the levels of Lp-PLA2, a risk factor for coronary heart disease (see Clinica No 931, p 19). The Santa Clara, California company says that Lp-PLA2 is independent of other known risk factors, including low-density lipoprotein cholesterol and C-reactive protein. The patent was licensed from GlaxoSmithKline, which discovered that Lp-PLA2 was associated with atherosclerotic plaque.